Search

• GSK and Genmab receive accelerated approval for Arzerra™

  Media

  Today, GlaxoSmithKline (GSK) and Genmab A/S (OMX: GEN) announced the accelerated approval of Arzerra TM (ofatumumab).

  https://www.gsk.com/en-gb/media/press-releases/gsk-and-genmab-receive-accelerated-approval-for-arzerra/

  First published: 26 October 2009

• GSK publishes 2008 Corporate Responsibility Report

  Media

  Details on new proposals to tackle diseases of the developing world.

  https://www.gsk.com/en-gb/media/press-releases/gsk-publishes-2008-corporate-responsibility-report/

  First published: 23 March 2009

• ViiV Healthcare shows more than 99% effectiveness in real-world studies for Apretude (cabotegravir long-acting), the only approved long-acting HIV PrEP, in data presented at IDWeek 2024

  Media

  Studies from OPERA and Trio cohorts provide further real-world evidence.

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-shows-more-than-99-effectiveness-in-real-world-studies-for-apretude/

  First published: 16 October 2024

• Two new GSK oral oncology treatments, BRAF-inhibitor Tafinlar® (dabrafenib) capsules and the first MEK-inhibitor Mekinist™ (trametinib) tablets, approved by FDA as single-agent therapies

  Media

  GSK announced today that the FDA has approved both TAFINLAR® (dabrafenib) and MEKINIST™ (trametinib).

  https://www.gsk.com/en-gb/media/press-releases/two-new-gsk-oral-oncology-treatments-braf-inhibitor-tafinlar-dabrafenib-capsules-and-the-first-mek-inhibitor-mekinist-trametinib-tablets-approved-by-fda-as-single-agent-therapies/

  First published: 29 May 2013

• ViiV Healthcare announces US FDA approval of the first-ever dispersible tablet formulation of dolutegravir, Tivicay PD, a once-daily treatment for children living with HIV

  Media

  ViiV Healthcare announces US FDA approval of the first-ever dispersible tablet formulation of dolutegravir.

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-us-fda-approval-of-the-first-ever-dispersible-tablet-formulation-of-dolutegravir/

  First published: 12 June 2020

• GSK publishes 2010 Corporate Responsibility Report

  Media

  In its CRR, GSK reiterated its commitment to building its business on strong values and ethical standards.

  https://www.gsk.com/en-gb/media/press-releases/gsk-publishes-2010-corporate-responsibility-report/

  First published: 27 March 2011

• ViiV Healthcare launches: A new specialist HIV company dedicated to delivering advances in HIV treatment and care

  Media

  CEO promises 'relentless pursuit' of new treatments

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-launches-a-new-specialist-hiv-company-dedicated-to-delivering-advances-in-hiv-treatment-and-care/

  First published: 02 November 2009

• GlaxoSmithKline and Human Genome Sciences receive European authorisation for Benlysta® (belimumab)

  Media

  GSK & HSG announced, EC has granted marketing authorisation for Benlysta as therapy in patients with active autoantibody-positive SLE.

  https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-human-genome-sciences-receive-european-authorisation-for-benlysta-belimumab/

  First published: 14 July 2011

• ViiV Healthcare announces US FDA approval for Rukobia (fostemsavir), a first-in-class treatment for HIV in adults with few treatment options available

  Media

  ViiV today announced that the US FDA has approved Rukobia (fostemsavir), 600 mg extended-release tablets.

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-us-fda-approval-for-rukobia-fostemsavir-a-first-in-class-treatment-for-hiv-in-adults-with-few-treatment-options-available/

  First published: 02 July 2020

• ViiV Healthcare announces FDA approval of Cabenuva (cabotegravir, rilpivirine), the first and only complete long-acting regimen for HIV treatment

  Media

  The approval is based on the pivotal phase III ATLAS and FLAIR studies that included more than 1,100 patients from 16 countries.

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-fda-approval-of-cabenuva-cabotegravir-rilpivirine-the-first-and-only-complete-long-acting-regimen-for-hiv-treatment/

  First published: 21 January 2021